Evidence map›Paper›PMID 28741623›Full record

ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2018

Effects of Suvorexant, a Dual Orexin/Hypocretin Receptor Antagonist, on Impulsive Behavior Associated with Cocaine.

Taylor A Gentile, Steven J Simmons, Mia N Watson, Krista L Connelly, Eugen Brailoiu, Yanan Zhang, John W Muschamp

Open access · bronzeAbstract read
In one paragraph

Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 68 citations in OpenAlex.

  1. Trial
  2. Selective orexin receptor cross-over treatment increases resilience and expression of neuroplastic signaling genes.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Annual Research Review: Perspectives on progress in ADHD science - from characterization to cause.Journal of child psychology and psychiatry, and allied disciplines · 2023
    Review
  13. Review
  14. Article
  15. Sleep-mediated regulation of reward circuits: implications in substance use disorders.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023
    Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Taylor A GentileCenter for Substance Abuse Research, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.
Steven J SimmonsCenter for Substance Abuse Research, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.
Mia N WatsonCenter for Substance Abuse Research, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.
Krista L ConnellyCenter for Substance Abuse Research, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.
Eugen BrailoiuCenter for Substance Abuse Research, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.
Yanan ZhangResearch Triangle Institute, Research Triangle Park, NC, USA.
John W MuschampCenter for Substance Abuse Research, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.
Temple University · USRTI International · US

Funding

TRAINING PROGRAM: DRUGS OF ABUSE RELATED NEUROPEPTIDEST32DA007237 · NIDA · TEMPLE UNIV OF THE COMMONWEALTH · PI ELLEN M UNTERWALD · 1988 to 2026
$10.6M
Orexin-1 Receptor Ligands for Drug AddictionR33DA032837 · NIDA · RESEARCH TRIANGLE INSTITUTE · PI ZHANG, YANAN · 2014 to 2015
$992k
NIDA NIH HHS R33 DA032837NIDA NIH HHS T32 DA007237
6 · The paper itself

Abstract

Hypothalamic hypocretin (orexin) peptides mediate arousal, attention, and reward processing. Fibers containing orexins project to brain structures that govern motivated behavior, including the ventral tegmental area (VTA). A number of psychiatric conditions, including attention deficit hyperactivity disorder (ADHD) and substance use disorders, are characterized by deficits in impulse control, however the relationship between orexin and impulsive behavior is incompletely characterized. The effects of systemic or centrally administered orexin receptor (OXR) antagonists on measures of impulsive-like behavior in rats were evaluated using the five-choice serial reaction time task (5-CSRTT) and delay discounting procedures. These paradigms were also used to test the capacity of OXR antagonists to attenuate acute cocaine-evoked impulsivity. Finally, immunohistochemistry and calcium imaging were used to assess potential cellular mechanisms by which OXR blockade may influence motor impulsivity. Suvorexant, a dual (OX

Indexed as

AnimalsAzepinesBenzoxazolesChoice BehaviorCocaineDelay DiscountingImpulsive BehaviorIsoquinolinesMaleMicroinjectionsNaphthyridinesOrexin Receptor AntagonistsOrexinsProto-Oncogene Proteins c-fosPyridinesRats1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea1-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-3,3-dimethyl-2-((4-pyridinylmethyl)amino)-1-butanoneAzepinesBenzoxazolesCocaineIsoquinolinesNaphthyridinesOrexin Receptor AntagonistsOrexinsProto-Oncogene Proteins c-fosPyridinessuvorexantTriazolesUrea

Identifiers

PMID28741623
PMCPMC5854790
OpenAlexW2738347122

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.